Ardelyx News

4,95 $ -1,39% -0,07 $
In : 4,4452 € | 21:02:26 Uhr Nasdaq | Mehr Kurse »
WKN: A116X0
ISIN: US0396971071
US-Symbol: ARDX
Typ: Aktie

Ardelyx News

  
10.10.19 Ardelyx to Host Analyst Day in New York PR Newswire
17.09.19 Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference PR Newswire
13.09.19 No Brainer Club: Weitere Empfehlungen steigen +151% und +110% sharedeals.de
12.09.19 Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation PR Newswire
03.09.19 Ardelyx: NBC-​Favorit mit +117% in drei Wochen sharedeals.de
03.09.19 Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment PR Newswire
03.09.19 Ardelyx: NBC-​Favorit mit +117% in drei Wochen Finanztrends
02.09.19 Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study PR Newswire
09.08.19 Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights PR Newswire
30.05.19 Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference PR Newswire
07.05.19 Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights PR Newswire
14.03.19 Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors PR Newswire
07.03.19 Ardelyx Announces Peer-​Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology PR Newswire
06.03.19 Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights PR Newswire
21.02.19 Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference PR Newswire
07.02.19 Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan PR Newswire
13.11.18 Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C PR Newswire
07.11.18 Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights PR Newswire
26.10.18 Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus PR Newswire
08.10.18 Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting PR Newswire
04.10.18 Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders PR Newswire
13.09.18 Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration PR Newswire
29.08.18 Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption PR Newswire
07.08.18 Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights PR Newswire
01.08.18 Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call PR Newswire
29.05.18 Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
22.05.18 Ardelyx Announces Pricing of Public Offering of Common Stock PR Newswire
21.05.18 Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank PR Newswire
21.05.18 Ardelyx Announces Proposed Public Offering of Common Stock PR Newswire
08.05.18 Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights PR Newswire
19.03.18 Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada PR Newswire
14.03.18 Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors PR Newswire
12.02.18 Ardelyx Announces Departure of Chief Scientific Officer PR Newswire
08.02.18 Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference PR Newswire
03.01.18 Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference PR Newswire
03.01.18 Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C PR Newswire
11.12.17 Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China PR Newswire
28.11.17 Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan PR Newswire
21.11.17 Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline PR Newswire
07.11.17 Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress PR Newswire
16.10.17 Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling PR Newswire
11.10.17 Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 PR Newswire
09.08.17 Ardelyx Focuses Resources on Late-​Stage Programs and Reports Second Quarter 2017 Operational Results PR Newswire
02.08.17 Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference PR Newswire
12.05.17 Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C PR Newswire
05.05.17 Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress PR Newswire
18.04.17 Ardelyx To Present at Upcoming Spring Medical Meetings PR Newswire
27.02.17 Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference PR Newswire
17.02.17 Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results PR Newswire
15.02.17 Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease PR Newswire

Newssuche